EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
The intention of this trial is to evaluate safety and efficacy of a combination treatment of EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.
Adenocarcinoma|Metastasis|Pancreas Neoplasms
DRUG: Gemcitabine alone|DRUG: EndoTAG-1 and Gemcitabine|DRUG: EndoTAG-1 and Gemcitabine|DRUG: EndoTAG-1 and Gemcitabine
Progression free survival, Median|6-month-survival-rate, 6 Months|Overall survival, Median
Incidence and percentage of patients with Adverse Events, 28 days after last patient out|Number of clinically significant abnormal laboratory values, Last patient out
The intention of this trial is to evaluate safety and efficacy of a combination treatment of EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.